Immunocore saw 70% of first-line patients alive at two years. Can two T-cell engagers really beat KIMMTRAK alone?
Immunocore reported 70% two-year survival with KIMMTRAK plus brenetafusp, but a randomised Phase 2/3 trial must confirm the signal.
Features & Analysis
Pharma & Biotech
Immunocore reports 70% two-year survival with dual T-cell engager combination in uveal melanoma
Immunocore’s brenetafusp plus Kimmtrak posted 70% two-year survival in 17 first-line uveal melanoma patients, prompting a Phase 2/3 trial.